Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 601–700 of 999
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
Poggio, T., Duyster, J., & Illert, A. L. (2018) · Cancers · doi:10.3390/cancers10090339 · Cited by 16
Primary central nervous system lymphoma: Novel precision therapies
Mondello, P., Mian, M., & Bertoni, F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.009 · Cited by 16
Myers, R. M., Dolan, J. G., & Teachey, D. T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1828067 · Cited by 17
Marton, C., Clémenceau, B., Dachy, G., Demerle, C., Derenne, S., Ferrand, C., Giverne, C., Latouche, J.-B., Lemée, L., Martinet, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02637-8 · Cited by 16
“Moreover, prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Wronski, M., Wesselingh, R., Kazzi, C., Seery, N., Ko, K., Li, J. J., Tan, T., Simpson, T., Abbott, C., Fleming, S. A., et al. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578717 · Cited by 17
Cao, G., Lei, L., & Zhu, X. (2019) · Medicine · doi:10.1097/md.0000000000017506 · Cited by 16
“high-dose group’s incidence was 3/9, indicating that a higher cell dose may increase the frequency of sCRS.([27]) Kochenderfer et al showed that grade 3 or 4 toxicities are associated with peak CAR peripheral blood mononuclear cell numbers and peak IL10 and IL-15 levels.”
BackgroundResultInfluentialAbbott, R. C., Iliopoulos, M., Watson, K. A., Arcucci, V., Go, M., Hughes‐Parry, H. E., Smith, P., Call, M. J., Cross, R. S., & Jenkins, M. R. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1440 · Cited by 18
Fully closed cell sorter for immune cell therapy manufacturing
Matsumoto, M., Tashiro, S., Ito, T., Takahashi, K., Hashimoto, G., Kajihara, J., Miyahara, Y., Shiku, H., & Katsumoto, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.012 · Cited by 18
“Molecular Therapy: Methods & Clinic This is an open access article under t (1:1) in patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphoma showed synergistic enhancement in antitumor activity.(15,18) Selective depletion of alloreactive cells following haploidentical transplantation and purification of g…”
BackgroundBui, J. K., Starke, C. E., Poole, N. H., Rust, B. J., Jerome, K. R., Kiem, H., & Peterson, C. W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.030 · Cited by 18
Alviano, A. M., Biondi, M., Grassenis, E., Biondi, A., Serafini, M., & Tettamanti, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407992 · Cited by 17
The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis
Mazetto, R. A. S. V., Monteiro, S. O. N., Bulhões, E., Defante, M. L. R., Antunes, V., Balieiro, C. C. A., Feitoza, L. P. G. D. C., Ferreira, A. L. C., Carvalho, A. M., & Guida, C. M. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14289 · Cited by 19
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 24
Sharpe, M. E. (2018) · Toxicologic Pathology · doi:10.1177/0192623317752101 · Cited by 15
Current trials for frontline therapy of mantle cell lymphoma
Steiner, R. E., Romaguera, J. E., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0556-x · Cited by 16
Prevention and treatment of relapse after stem cell transplantation by cellular therapies
Falkenburg, F., Ruggiero, E., Bonini, C., Porter, D., Miller, J. C., Malard, F., Mohty, M., Kröger, N. M., & Kolb, H. J. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0227-0 · Cited by 14
Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
Sawaisorn, P., Atjanasuppat, K., Anurathapan, U., Chutipongtanate, S., & Hongeng, S. (2020) · Vaccines · doi:10.3390/vaccines8040753 · Cited by 16
“To date, the immunophenotype of T cells is well understood as an essential parameter in safety and efficacy features in CAR T products [50,88].”
BackgroundChávez, J. C., Yassine, F., Sandoval-Sus, J. D., & Kharfan‐Dabaja, M. A. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2020-0021 · Cited by 17
Wang, X., Luo, W., Chen, Z., Li, C., Zhou, J., Huang, Z., Tang, L., Wu, J., Wu, Z., Li, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010822 · Cited by 19
“We also acknowledge the Medical Sub-center of Analytical and Testing Center at Huazhong University of Science and Technology for their technical support.”
RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function
Zhu, X., Li, W., Gao, J., Shen, J., Xu, Y., Zhang, C., & Qian, C. (2023) · Medical Oncology · doi:10.1007/s12032-022-01913-7 · Cited by 15
Wang, W., Zhang, D., Sun, L., Zhang, Z., Zhang, Y., Zhang, Y., Zhang, Y., & Zhang, M. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114090 · Cited by 15
Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 15
Colina, A. S., Shah, V., Shah, R. K., Kozlik, T., Dash, R. K., Terhune, S. S., & Zamora, A. E. (2024) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2024.1310002 · Cited by 15
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 15
Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 17
“In particular, a close association persists between the emergence of ICANS and elevated IL-6 levels following treatment [22,28,171].”
BackgroundThe potential for chemotherapy-free strategies in mantle cell lymphoma
Martin, P., Ruan, J., & Leonard, J. P. (2017) · Blood · doi:10.1182/blood-2017-05-737510 · Cited by 14
Wudhikarn, K., & Park, J. H. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1761967 · Cited by 21
Gotti, M., Defrancesco, I., D’Angelo, M., Basso, S., Crotto, L., Marinelli, A., Maccalli, C., & Iaconianni, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565236 · Cited by 16
“Experiences at the NCI (55) and Fred Hutchinson Cancer Center (56) demonstrated that aggressive lymphodepleting regimens are associated with the increase of both CAR-T cell expansion and toxicity.”
BackgroundThe toxicity of cell therapy: Mechanism, manifestations, and challenges
Jin, Y., Dong, Y., Jin, Z., Sun, J., Liu, Y., & Chen, Y. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.4100 · Cited by 21
“However, it was reported that the addition of fludarabine to cyclophosphamide improved the persistence of CAR-T cells than cyclophosphamide alone (Turtle et al., 2016; Turtle et al., 2016) but with higher level of CRS and neurological toxicity.”
BackgroundMethodInfluentialChoi, S. H., Pegues, M. A., Lam, N., Geldres, C., Vanasse, D., & Kochenderfer, J. N. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.215 · Cited by 14
Li, J., Wu, Z., & Zhao, N. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01056-8 · Cited by 17
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
Galva, L. D. C., Cai, L., Shao, Y., & He, Y. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.01.002 · Cited by 14
Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas
Gajzer, D. C., & Fromm, J. R. (2025) · Cancers · doi:10.3390/cancers17050814 · Cited by 16
Zhang, M., Wang, Y., Chen, X., Zhang, F., Chen, J., Zhu, H., Li, J., Chen, Z., Wang, A., Xiao, Y., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03161-1 · Cited by 16
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Rothemejer, F. H., Lauritsen, N. P., Søgaard, O. S., & Tolstrup, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253395 · Cited by 17
Hirayama, A. V. V., Wright, J. H., Smythe, K. S., Fiorenza, S., Shaw, A. N., Gauthier, J., Maloney, D. G., Naresh, K. N., Yeung, C. C. S., & Turtle, C. J. (2024) · HemaSphere · doi:10.1002/hem3.142 · Cited by 16
Ju, A., Choi, S., Jeon, Y., & Kim, K. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2024.0037 · Cited by 15
Ortí, G., Peczynski, C., Boreland, W., O'Reilly, M. A., Bonin, M. V., Balduzzi, A., Besley, C., Kałwak, K., Ryhänen, S. J., Güngör, T., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02467-5 · Cited by 16
Lu, I., Müller‐Miny, L., Krekeler, C., Cheung, P. F., Antonopoulou, G., Jeibmann, A., Schulte‐Mecklenbeck, A., Kerl, K., Call, S., Reicherts, C., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01498-6 · Cited by 18
Eltoukhy, H. S., Sinha, G., Moore, C. A., Sandiford, O. A., & Rameshwar, P. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.011 · Cited by 14
Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
Mina, A. A., Vakkalagadda, C. V., & Pro, B. (2019) · Cancers · doi:10.3390/cancers11030421 · Cited by 15
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?
Namuduri, M., & Brentjens, R. J. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1753501 · Cited by 14
Sellner, L., Fan, F., Giesen, N., Schubert, M., Goldschmidt, H., Müller‐Tidow, C., Dreger, P., Raab, M. S., & Schmitt, M. W. (2020) · International Journal of Cancer · doi:10.1002/ijc.33002 · Cited by 16
“For the earlier CD19-directed CAR-Ts, anti-murine CAR host immune responses were reported that may have limited efficacy by prevention of in vivo expansion.(19) As a result, there has been increasing use of human-derived scFvs in newer BCMA-”
BackgroundAcharya, U. H., & Walter, R. B. (2020) · Cancers · doi:10.3390/cancers12123617 · Cited by 13
Innamarato, P., & Pilon‐Thomas, S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104277 · Cited by 14
Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma
Komanduri, K. V. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01749 · Cited by 14
The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
Guo, Z., Zhang, Y., Fu, M., Zhao, L., Wang, Z., Xu, Z., Zhu, H., Lan, X., Shen, G., He, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652924 · Cited by 13
Sonzogni, O., Zak, D. E., Sasso, M. S., Lear, R., Muntzer, A., Zonca, M., West, K., Champion, B. R., & Rottman, J. B. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2029070 · Cited by 13
Jeyakumar, N., & Smith, M. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887866 · Cited by 14
“CAR products engineered with defined 1:1 CD4:CD8 ratios have also shown improved antitumor activity relative to unselected Tcells in mouse models (50) and have demonstrated efficacy in patients with r/r DLBCL (51).”
BackgroundMarhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 16
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Himmels, P., Nguyen, T. T. T., Caunt, M., Arrazate, A., Yeung, S., Burton, J., Clark, R., Tótpál, K., Jesudason, R., Yang, Y. A., et al. (2023) · EMBO Reports · doi:10.15252/embr.202255532 · Cited by 13
“…approaches such as chimeric antigen receptor (CAR) T cells and CD3-bispecific antibodies, which have shown promising clinical activity in hematological malignancies (Bargou et al , 2008; Kalos et al , 2011; Brentjens et al , 2013; Maude et al , 2014; Turtle et al , 2016; Kantarjian et al , 2017).”
Next-generation immunotherapies for lymphoma: one foot in the future
Manson, G., & Houot, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy032 · Cited by 17
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
Xue, Y., Lai, X., Li, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607362 · Cited by 13
Kean, L. S. (2018) · Blood · doi:10.1182/blood-2018-02-785881 · Cited by 16
Blood–brain barrier dysfunction in intensive care unit
Guennec, L. L., & Weiss, N. (2023) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.01.001 · Cited by 13
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Yu, T., Jiang, W., Wang, Y., Zhou, Y. Y., Jiao, J., & Wu, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5628 · Cited by 14
“Turtle et al (226) conducted a study that revealed that tocili‑ zumab, an anti‑human IL‑6 receptor monoclonal antibody, was the primary management option for patients experiencing moderate to severe CRS. Li et al (10) emphasized the impor‑ tance of timely tocilizumab treatment for elderly patients…”
BackgroundAcute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
Jing, J., Ma, Y., Xie, Z., Wang, B., Chen, Y., Chi, E., Wang, J., Zhang, K., Wang, Z., & Li, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410519 · Cited by 15
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms
Kearl, T. J., Furqan, F., & Shah, N. N. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10228-0 · Cited by 16
“Compared to healthy donors, T cells from NHL patients have decreased fractions of early-lineage T cells compared to healthy donors [65], and this may result in less effective CAR T cells.”
Gauthier, J., Liang, E. C., Huang, J. J., Kimble, E. L., Hirayama, A. V. V., Fiorenza, S., Voutsinas, J. M., Wu, Q. V., Jaeger-Ruckstuhl, C. A., Pender, B. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015314 · Cited by 14
“6,11,12 The identi fi cation of anti-CAR immune responses suggested reducing the immunogenicity of CD19 CAR T-cells may improve outcomes.”
Renninger, J. P., Kurz, L., & Stein, H. (2025) · Drug Safety · doi:10.1007/s40264-025-01538-5 · Cited by 18
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 16
Yang, S., Wang, W., Rao, Q., Xu, Y., Zhang, S., Qu, Y., Zhuang, Q.-C., Mao, J., Sun, L., Geng, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012331 · Cited by 16
Taştan, C., Kançağı, D. D., Turan, R. D., Yurtsever, B., Çakırsoy, D., Abanuz, S., Yılancı, M., Seyis, U., Özer, S., Mert, S., et al. (2020) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2020.2020.0070 · Cited by 16
“The first clinical trials using transgenic CAR-T cells were performed in patients having hematological cancers including B-cell acute lymphoblastic leukemia (ALL) and nonHodgkin lymphoma (NHL), which showed improved response rates ranging from 50% to 85% with a significant level of diseasefree and overall survival [4,…”
BackgroundBanerjee, R. K., Fakhri, B., & Shah, N. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924370 · Cited by 12
“robust CAR-T cell expansion in vivo may be associated with CRS as well [14,25,26,28].”
BackgroundCell delivery devices for cancer immunotherapy
Wen, P., Wu, W., Wang, F., Zheng, H., Liao, Z., Shi, J., Zhu, C., Zhao, P., Cheng, H., Li, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.041 · Cited by 13
Yoon, D. H., Koh, Y., Jung, M.-Y., Kwak, J.-E., Shin, E., Hwang, Y. K., & Kim, W. S. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.12.025 · Cited by 14
Masilamani, M., Jawa, V., Dai, Y., Das, R., Park, A., Lamba, M., Wu, F., Zheng, X., Lu, E., Gleason, C. R., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2991 · Cited by 14
Alb, M., Reiche, K., Rade, M., Sewald, K., Loskill, P., Cipriano, M., Maulana, T. I., van der Meer, A. D., Weener, H. J., Clerbaux, L., et al. (2024) · Journal of Immunotoxicology · doi:10.1080/1547691x.2024.2345158 · Cited by 15
“In addition, if not fully humanized, the non-human parts of the scFv might induce an immune response leading to premature elimination of CAR T cells rendering subsequent infusions difficult or even impossible (Turtle et al. 2016; Sommermeyer et al. 2017).”
Producing proT cells to promote immunotherapies
Singh, J., & Zúñiga‐Pflücker, J. C. (2018) · International Immunology · doi:10.1093/intimm/dxy051 · Cited by 12
CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm
Hill, L. C., Lulla, P., & Heslop, H. E. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.54 · Cited by 13
Phase I CAR-T Clinical Trials Review
Bulsara, S., Wu, M.-F., & Wang, T. (2022) · Anticancer Research · doi:10.21873/anticanres.16076 · Cited by 11
Zheng, N., Long, Y., Bai, Z., Li, J., Wang, H., Song, D., Liu, H., Shi, J., & Zhao, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04779-z · Cited by 11
“Clinical trials have demonstrated that this CAR design achieves high rates of complete remission [24].”
CD8+ T cell-based immunotherapy: Promising frontier in human diseases
Ton, N. Q. C., Deka, G., & Park, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116909 · Cited by 12
Neurotoxicities After CAR T-Cell Immunotherapy
Gust, J., Ceppi, F., & Turtle, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00007-x · Cited by 12
Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., Colantonio, S., & Blonder, J. (2021) · Oncotarget · doi:10.18632/oncotarget.28072 · Cited by 12
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy
Fiorenza, S., Lim, S. Y. T., Laszlo, G. S., Kimble, E. L., Phi, T.-D., Lunn-Halbert, M. C., Kirchmeier, D. R., Huo, J., Kiem, H., Turtle, C. J., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200854 · Cited by 13
Young, P. A., Yamada, R. E., Trinh, K. R., Vasuthasawat, A., Oliveira, S. N. D., Yamada, D. H., Morrison, S. L., & Timmerman, J. M. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0030 · Cited by 11
Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy
Appelbaum, J., & Milano, F. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0476-4 · Cited by 12
To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors
Mondino, A., & Manzo, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01915 · Cited by 14
“Whether increasing the availability of CD4 T cell help might be beneficial to ACT approaches, and whether predefined CD4 and/or CD8 T cell compositions at various degree of differentiation would ameliorate ACT therapeutic potential is currently being investigated in a number of ongoing trials (91, 114).”
BackgroundThe emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
Khuat, L. T., Dave, M., & Murphy, W. J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1966262 · Cited by 13
Schubert, M., Berger, C., Kunz, A. B., Schmitt, A., Badbaran, A., Neuber, B., Zeschke, S., Wang, L., Riecken, K., Hückelhoven‐Krauss, A., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5338 · Cited by 11
“CAR T cells as cellular products display variable pharmaco‐ kinetic and pharmacodynamic profiles that depend not only on patient‐specific characteristics but also on the administered CAR T cell dose, lymphodepletion therapy and targeted disease (25).”
BackgroundZalka, C. V. (2012) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 23
Augmentation of Solid Tumor Immunotherapy With IL‐12
Geils, C., & Kathrein, K. L. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.70000 · Cited by 11
Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma
Strati, P., Patel, S., Nastoupil, L. J., Fanale, M. A., Bollard, C. M., Lin, A. Y., & Gordon, L. I. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200549 · Cited by 11
Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
Shah, U. A., & Smith, E. L. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000379 · Cited by 11
Chen, R., Wang, M., Liu, Q., Wu, J., Huang, W., Li, X., Du, B., Xu, Q., Duan, J., Jiao, S., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.022 · Cited by 10
Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy
Vinanica, N., Yong, A. Y. L., Wong, D., Png, Y. T., Seow, S. V., Imamura, M., & Campana, D. (2019) · Blood · doi:10.1182/blood.2019001645 · Cited by 11
Wang, S., Moore, T. V., Dalheim, A. V., Scurti, G. M., & Nishimura, M. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-92808-6 · Cited by 13
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
Liu, Q., Liu, Z., Wan, R., & Huang, W. (2022) · Cancers · doi:10.3390/cancers14184452 · Cited by 11
Seipel, K., Frey, M., Nilius, H., Akhoundova, D., Banz, Y., Bacher, U., & Pabst, T. (2023) · Current Oncology · doi:10.3390/curroncol30120762 · Cited by 12
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Cordeiro, A., Durisek, G., Batista, M. V., Schmidt, J., Lima, M. J. G. D., & Bezerra, E. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1404351 · Cited by 12
Treatment approaches of hard-to-treat non-Hodgkin lymphomas
Nandagopal, L., & Mehta, A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1283214 · Cited by 10
What CAR Will Win the CD19 Race?
Quintás‐Cardama, A. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1070 · Cited by 10
“By contrast, the TRANSCENDNHL-001 study provided liso-cel at afixed 1:1 CD4: CD8 ratio in an attempt to gain more control over the expansion of the product post infusion and to minimize toxicity (31).”
BackgroundResultHuang, C., Zhang, H., Ho, J., Liu, R., Wang, L., Kuang, N., Zheng, M., Liu, L., & Li, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11882 · Cited by 11
Gauthier, J., & Maloney, D. G. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.010 · Cited by 11
Qi, J., Lv, X., Chen, J., Wang, H., Chu, T., Tang, Y., Pan, T., Zhou, M., Cai, C., Ren, Y., et al. (2021) · Hematological Oncology · doi:10.1002/hon.2931 · Cited by 11
Wang, Y., Wang, L., Zeng, Y., Hong, R., Zu, C., Yin, E. T. S., Zhao, H., Wei, G., Yang, L., Jin, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755584 · Cited by 11
“Several trials found that an appropriately defined CD4/CD8 ratio can improve the efficacy of CAR-T cells (23, 24).”
BackgroundMiskey, C., Amberger, M., Reiser, M., Prommersberger, S., Beckmann, J., Machwirth, M., Einsele, H., Hudecek, M., Bonig, H. B., & Ivics, Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/675009 · Cited by 10
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia
Colonne, C. K., Kimble, E. L., & Turtle, C. J. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2420614 · Cited by 10
“Chimeric antigen receptor (CAR)-modified T (CAR-T) cell therapy has shown great promise in the treatment of refractory B-cell malignancies and multiple myeloma (MM) [8–17].”
Ozog, S., Krantz, E. M., Tindbaek, K., Munoz, J., Liu, W. L., Chalal, C., Pernikoff, S., Yahya, K., Stevens‐Ayers, T., Dasgupta, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71473-1 · Cited by 11
A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy
Burchett, R., Walsh, S. R., Wan, Y., & Bramson, J. L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.003 · Cited by 10
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.